INTRODUCTION
Transepithelial transfer of polymeric J chain-containing IgA and IgM into secretions is well documented in man and animals. At several mucosal sites secretory component (SC)', an epithelial cell surface glycoprotein, acts as a specific receptor and initiates an endocytotic vesicular transport to lumen of polymeric IgA (p-IgA) and IgM synthesized by submucosal plasmacytes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recently, it has been shown that pIgA is also actively transported from serum into bile by the hepatocyte of the rat and other mammals (11) (12) (13) (14) (15) . Suggested roles for this transport are reinforcement of intestinal immunity (16, 17) and clearance of p-IgA antibodies and immune complexes from blood (18) (19) (20) (21) .
In man, the concentration, source, and significance of biliary IgA are controversial. The presence of IgA was first demonstrated in gallbladder bile (22, 23) . In hepatic bile, Dive and Heremans (24, 25) measured secretion-to-serum concentration ratios for several proteins and showed their passive, molecular weightdependent transport from serum. For IgA, found at similar concentrations as IgG, they suggested the existence of an additional local origin. Recently, Nagura et al. (26) also measured the concentration of IgG, IgA, and IgM in hepatic bile, but not in serum, and found predominantly 11S sIgA in bile with virtually undetectable IgG and IgM. They presented elegant immunohistochemical evidence for a SC-mediated endocytotic transport of p-IgA across the biliary epithelium, and like others (27) , could not demonstrate SC on and in hepatocytes, despite positive results of another group (28) .
In the present article, we measured the concentrations of eight serum proteins in hepatic bile, saliva, and serum, considering separately monomeric (m-IgA) and p-IgA. To evaluate the selectivity of excretions of IgA or of other proteins in secretions, all protein concentrations in bile and saliva were related to their corresponding serum concentrations. However, secretions display large variations in protein concentrations both between different individuals and, in the same individual, between different secretions. Thus, to allow quantitative comparisons between different individuals and between bile and saliva, the individual secretion-to-serum concentration ratios for each protein were "normalized" by expressing results relatively to albumin (Alb), which, in bile (24, 29) , and saliva (25, 30) , is entirely derived from serum. Thus, results were expressed as Alb-relative secretion-to-serum concentration ratios (S/S-ARCR). S/S-ARCR (secretion-to-serum concentration ratio) protein (secretion-to-serum concentration ratio) Alb In addition, the proportion of the selective excretion of IgA in bile and saliva, which derived from a serumto-secretion transport, was quantitated in five patients after intravenous injection of polyclonal '251-p-IgA and/or '3'I-m-IgA by calculation of their secretion-toserum specific activity ratios (S/S-SAR). (31) in serum, except for a2M, orosomucoid, and SC which, like all proteins in secretions, were measured by immunoradiometric assays (IRMA), all performed as described for IgA (32) . For each assay, seven standards were obtained from a pool of 1,000 blood donors, also used for IN. Standard ranges used, with coefficients of variation <8%, were, respectively, 3-100 ng/ ml (Alb), 2-60 ng/ml (orosomucoid), ng/ml (transferrin), ng/ml (IgG), 4-100 ng/ml (IgA), 5-500 ng/ml (a2M), ng/ml (IgM), and 10-400 ng/ml (SC). Purified 11S sIgA (33) Radioiodination was performed with chloramine T (41). Free label was separated by gel filtration on disposable Sephadex G-50 columns, prewashed with sterile human serum albumin in PBS. The labeled proteins were passed through a Millipore (0.22 sm) filter also prewashed with human serum albumin. Pyrogenicity of the labeled proteins was tested by injecting rabbits intravenously with 10 times the doses injected into humans. The yield of labeling varied between 48 and 67%, and <4% of the radioactivity was soluble in TCA (100 g/liter).
METHODS

Isotopic studies
Isotopic studies were performed in four of the patients with cystic or T tube drainage (patients 2-5) and in the patient 1 with total biliary drainage. Patients London) whereby most of the low molecular weight label was removed. Membrane-bound counts per minute were included in this measurement. The percentage of anti-a-precipitable radioactivity was measured by mixing an aliquot (0.3-1.0 ml) of the concentrated samples (>2,000 counts of either isotope per 3 min) with a slight excess (1-2 ml) of goat anti-a-chain, or anti-y-chain as control, incubating 3 h at 37°C, adding 8 ml of sheep antigoat IgG (antibody excess) and further incubating for 2-4 h at room temperature and overnight at 4°C. After centrifugation, the precipitates were washed with 4 ml of PBS and counted enough time to accumulate 1,000 counts in the controls. In patient 3, specific activity was also measured in four subsequent bile collections.
Saliva. Two equal volumes of saliva, collected at the beginning and at the end of bile collection, were pooled. IgA concentrations were measured on this pool, whereas nondialyzed and anti-a-precipitable radioactivities were measured after 20-fold concentration, as for bile, but on 10 ml of the saliva pools.
Serum. The concentrations of m-and p-IgA in serum were measured on a sample taken before the intravenous injection; these concentrations were assumed to be constant. Serial samples (2 ml) were obtained after the intravenous injection, counted (3 min) and their anti-a-precipitable radioactivities measured to construct a specific activity-disappearance curve. The serum specific activity of m-and dIgA to be compared with those in bile and saliva were derived from that curve at mid-time of the bile collection period. The serum anti-a-precipitable radioactivities were obtained by direct immunoprecipitation (2 ml of anti-a/0.25 ml of serum), using anti-al-antitrypsin as control.
Anti-SC-precipitable radioactivity was measured in bile in the same way as anti-a-precipitable radioactivity, using anti-SC instead of anti-a-antiserum.
Fractional catabolic rates were calculated over 4.5 d according to Matthews (42) and compared with those obtained in eight healthy volunteers injected with the same labeled m-and d-IgA.
In patient 1, bile was also collected immediately after intravenous injection, allowing to measure the total amount of anti-a-precipitable radioactivity excreted in 24 h.
Statistical analysis
Means and standard deviations relating to protein concentrations were obtained from their log values and expressed as the antilog values. S/S-ARCR were compared using the nonparametric Wilcoxon rank test for paired values (43) .
RESULTS
Size distribution of IgA and SC in serum and secretions. In serum (Fig. 2) , IgA was eluted from SDGU in a major 7S peak and one or two minor peaks of polymer, with CS of 10-10.5S and 12-13S, which represented 5-24% (mean = 13%) of the total serum IgA.
In bile (Fig. 2) , the IgA profile displayed a less important 7S peak, and two or three peaks of polymers with CS of -11-11.5S, 13S, and 15S, which together represented 43-88.5% (mean = 70%) of the total bile IgA. To each of these IgA peaks corresponded a peak of SC. An additional, often poorly resolved 10-10.5S IgA peak was found in most biles without corresponding SC peak. FSC with a CS of 4.6S was found in all biles (8-44% of total SC; mean = 29%), as well as small 18-19S SC peak that corresponded to the IgM peak.
In saliva (not shown), IgA and SC SDGU profiles were similar to those in bile, but with a much smaller 7S IgA peak, no 10-10.5S IgA peak, and in several cases, traces of anti-a-chain reacting material of smaller CS than 7S. Polymers represented 74-98% (mean = 93%) of the total IgA.
Protein concentration. Means and ranges of protein concentrations in serum, bile, and saliva are listed in Table I Size distribution of radioactivity in concentrated bile and saliva. In bile, the 125I-d-IgA peak shifted from a CS of 10.5S toward a peak with larger CS, which was largely superposed with the profile of pIgA (Fig. 5) ; 1311-m-IgA in bile was largely superposable to the 7S IgA peak as illustrated for patient 5 (Fig. 6 ).
In saliva, most of the radioactivity of both m-and d-IgA was found with CS below 7S (Figs. 5 and 6 ).
S/S-SAR of m-and d-IgA. The radioactivities, their anti-a-precipitable percentages, the total IgA amounts, and the S/S-SAR are listed for 1251-d-IgA in Table II , and for '3II-m-IgA in Table III . The percentages of anti-a-precipitable '"I-d-IgA radioactivities, which were also specifically precipitable with anti-SC-antiserum, were respectively 76, 64, 49, and 53% for patients 1-4, whereas they were not significant for '311-m-IgA. The evolution of the specific activity in bile was comparable to that in serum as illustrated in Fig. 4 for patient 3 in whom five collections of bile were obtained after injection.
Individual total S/S-ARCR of IgG, m-IgA, and pIgA for the four injected patients are listed in Table  IV together with their corresponding serum-derived S/S-ARCR (S/S-ARCR X S/S-SAR) of m-and p-IgA, and their means±SD are illustrated in Fig. 7 . For pIgA in bile, the serum-derived S/S-ARCR (mean = 4.9) represented 51% of the total S/S-ARCR (mean = 9.6), (26) .
Our total IgA concentrations in bile are consistently lower than those reported by Nagura et al. (26) and are, in contrast to their results, similar to the levels of IgG. Technical differences related to the size heterogeneity influence upon their immunoassay, and to the sensitivity of their radial immunodiffusion assays for IgG and IgM in bile, may explain these discrepancies. However, the absence of simultaneous serum study by this group makes their results difficult to compare with ours.
In saliva, our S/S-ARCR results show a pattern broadly similar to bile, but with a much greater se- Table II .
Nonultrafiltrated radioactivity after 20-fold concentration; it represented 52±18% of total bile radioactivity and 16±4% of total saliva radioactivity. § NS: <200 counts above the 1,000 counts of the control.
lective excretion of p-IgA, -16 times that in bile. Our isotopic studies, however, indicate that only 1.6% of total salivary p-IgA originated from serum, as compared with 50% in bile, pointing to a much greater contribution of local synthesis of IgA. Such a serumto-saliva transport of p-IgA, although subject to large errors due to a low percentage of anti-a-precipitable counts, is nevertheless in agreement with results on serum and saliva of IgA myeloma patients (44) , and on canine saliva using intravenously injected labeled p-IgA (25, 30) . It is probable that proteins other than IgA and IgM also reach secretions by mechanisms different from simple molecular weight-dependent passive transfer from serum, as suggested by our S/S-ARCR results for transferrin in bile and saliva or for IgG and a2M in saliva.
Since the daily output of hepatic bile and of saliva are 1 liter, roughly 28 mg of p-IgA will be transported from serum into external secretion for bile as compared with 3 mg for saliva. The daily total contribution to intestinal IgA should be of -77 mg of IgA for bile as compared with 206 mg for saliva.
The serum-derived p-IgA in bile was shown, by immunoprecipitation and by the shift of the 125I-d-IgA toward a greater CS in bile, to be significantly associated with SC. The studies by SDGU on the 17 bile samples, however, regularly documented a significant proportion of serum-type 10-10.5S IgA not associated with SC, in contrast to saliva. We also identified FSC in bile in substantial amounts, as well as SC sedimenting together with IgM. The finding of FSC in normal bile as well as in bile of an IgA-deficient subject (45) (47) . However, in contrast to Nagura et al. (26) and others (27) , another group (28) found intrahepatocyte SC and IgA, using amplified immunoperoxidase techniques but surprisingly, they found less SC and IgA staining in bile duct cells. In addition, a particular relationship between SC and hepatocytes was suggested by the rapid fall of the high serum SC concentration observed in patients with acute hepatitis when fulminant massive parenchymal necrosis occurred (48) . It seems likely that SC-mediated endocytotic transepithelial transfer of IgA through bile ducts explains the accumulation of locally synthesized IgA in bile. A similar transfer could also occur for IgM, which in man, in contrast to rats, has a higher noncovalent affinity for SC than does p-IgA (49, 50) and is also SC-transported in exocrine secretions (10, 51) . Regarding the serum-to-bile selective transport of pIgA, our data do not allow to distinguish between a selective transport mediated by both hepatocytes and bile duct cells, or by the latter only as suggested by Nagura et al. (26) . However, our data show a much smaller transfer of p-IgA from serum to bile than in rats and rabbits, in which hepatocyte synthesis of SC has been demonstrated (52) (53) (54) . After intravenous injection into rats and rabbits of the same iodine-labeled Serum-derived S/S-ARCR obtained by multiplying each total S/S-ARCR by its corresponding S/S-SAR to be found in Tables II and  III and with 0.53% over 8 h as reported by others (55) . The absolute concentration of p-IgA is 5-30 times larger in bile than in serum for rats (56, 57) and rabbits (40) , whereas in man, levels of p-IgA in bile are about one-fourth of those in serum. S/S-ARCR values for pIgA in hepatic bile of rats (58) and rabbits (40) are between 200 and 1,000 as compared with about 22 in humans, and in rats virtually all of the bile IgA is serum-derived. It is tempting to relate this striking quantitative difference to the presence of easily detectable SC in rat and rabbit, but not in human hepatocytes.
In conclusion, selective transport of p-IgA in human bile occurs from both serum and nonserum (local) origin. When compared with the rat and rabbit, it plays a much less significant role in the clearance of circulating IgA and in the contribution to sIgA in intestinal secretions.
